Tofé VI, Bagán
L, Bagán JV. Osteonecrosis of the jaws associated with denosumab: Study of
clinical and radiographic characteristics in a series of clinical cases. J Clin
Exp Dent. 2020;12(7):e676-81.
doi:10.4317/jced.57019
https://doi.org/10.4317/jced.57019
_________________________________
References
|
1.
Pollock RA, Brown TW, Rubin DM, Rubin DM.;"Phossy Jaw" and
"Bis-phossy Jaw"; of the 19th and the 21st Centuries: The
Diuturnity of John Walker and the Friction Match. Craniomaxillofac Trauma
Reconstr. 2015;8:262-70. |
|
|
|
|
|
2.
Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws,
American Association of Oral and Maxillofacial Surgeons. American Association
of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related
osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369-76. |
|
|
|
|
|
3.
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al.
American association of oral and maxillofacial surgeons position paper on
medication-related osteonecrosis of the jaw - 2014 update. J Oral Maxillofac
Surg. 2014;72:1938-56. |
|
|
|
|
|
4.
Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, DrudgeCoates
L, et al. Medication-related osteonecrosis of the jaw: definition and best
practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral
Pathol Oral Radiol. 2019;127:117-35. |
|
|
|
|
|
5.
Malan J, Ettinger K, Naumann E, Beirne OR. The relationship of denosumab
pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol
Oral Radiol. 2012;114:671-676. |
|
|
|
|
|
6.
Baron R, Ferrari S, Russell RGG. Denosumab and bisphosphonates: Different
mechanisms of action and effects. Bone. 2011;48:677-92. |
|
|
|
|
|
7.
Data sheet Prolia (denosumab). European Medicines Agency. See:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicine s/001120/human_med_001324.jsp&mid=WC0b01ac058001d124. |
|
|
|
|
|
8.
Data sheet Xgeva (denosumab). European Medicines Agency. See:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicine
s/002173/human_med_001463.jsp&mid=WC0b01ac058001d124. |
|
|
|
|
|
9.
Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by
antiRANK ligand therapy. Br J Oral Maxillofac Surg. 2010;48:221-3. |
|
|
|
|
|
10.
Peddi P, Lopez-Olivo MA, Pratt GF, Suarez-Almazor ME. Denosumab in patients
with cancer and skeletal metastases: a systematic review and meta-analysis.
Cancer Treat Rev. 2013;39:97-104. |
|
|
|
|
|
11.
Di Fede O, Panzarella V, Mauceri R, Fusco V, Bedogni A, Lo Muzio L, et al.
The dental management of patients at risk of medication-related osteonecrosis
of the jaw: New paradigm of primary prevention. Biomed Res Int. 2018:2684924. |
|
|
|
|
|
12.
Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, et al.
Denosumab for Prevention of Fractures in Postmenopausal Women with
Osteoporosis. N Engl J Med. 2009;361:756-65. |
|
|
|
|
|
13.
Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and
remodeling. Arch Biochem Biophys. 2008;473:139-46. |
|
|
|
|
|
14.
Bagan J, Peydró A, Calvo J, Leopoldo M, Jiménez Y, Bagan L.
Medication-related osteonecrosis of the jaw associated with bisphosphonates
and denosumab in osteoporosis. Oral Dis. 2016;22:324-9. |
|
|
|
|
|
15.
Hoefert S, Yuan A, Munz A, Grimm M, Elayouti A, Reinert S. Clinical course
and therapeutic outcomes of operatively and non-operatively managed patients
with denosumab-related osteonecrosis of the jaw (DRONJ). J
Cranio-Maxillofacial Surg. 2017;45:570-8. |
|
|
|
|
|
16.
Thumbigere-Math V, Tu L, Huckabay S, Dudek AZ, Lunos S, Basi DL, et al. A
Retrospective Study Evaluating Frequency and Risk Factors of Osteonecrosis of
the Jaw in 576 Cancer Patients Receiving Intravenous Bisphosphonates. Am J
Clin Oncol. 2012;35:386-92. |
|
|
|
|
|
17.
Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al.
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated
analysis from three blinded active-controlled phase III trials in cancer
patients with bone metastases. Ann Oncol. 2012;23:1341-7. |
|
|
|
|
|
18.
Wang Q-Z, Liu J-Y, Pan J. [Progress on medication-related osteonecrosis of
the jaw]. Hua Xi Kou Qiang Yi Xue Za Zhi. 2018;36:568-72. |
|
|
|
|
|
19.
de Boissieu P, Kanagaratnam L, Mahmoudi R, Morel A, Dramé M, Trenque T, et
al. Adjudication of osteonecrosis of the jaw in phase III randomized
controlled trials of denosumab: a systematic review. Eur J Clin Pharmacol.
2017;73:517-23. |
|
|
|
|
|
20.
Aljohani S, Gaudin R, Weiser J, Tröltzsch M, Ehrenfeld M, Kaeppler G, et al.
Osteonecrosis of the jaw in patients treated with denosumab: A multicenter
case series. J Cranio-Maxillofacial Surg. 2018;46:1515-25. |
|
|
|
|
|
21.
Aljohani S, Fliefel R, Ihbe J, Kühnisch J, Ehrenfeld M, Otto S. What is the
effect of anti-resorptive drugs (ARDs) on the development of medication-related
osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic
review. J Cranio-Maxillofacial Surg. 2017;45:1493-502. |
|
|
|
|
|
22.
Tsuchimochi M, Kurabayashi T. Symposium: Imaging modalities for drug-related
osteonecrosis of the jaw (1), role of imaging in drug-related osteonecrosis
of the jaw: An up-to-date review (secondary publication). Jpn Dent Sci Rev
[Internet]. 2019;55:1-4. |
|
|
|
|
|
23.
Baba A, Ojiri H, Goto TK, Ikeda K, Yamauchi H, Ogino N, et al. Symposium:
Imaging modalities for drug-related osteonecrosis of the jaw (4), CT and MR
imaging findings of antiresorptive agent-related osteonecrosis of the
jaws/medication-related osteonecrosis of the jaw (secondary publication). Jpn
Dent Sci Rev. 2019;55:58-64. |
|
|
|
|
|
24.
Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al.
Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of
the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner
Metab. 2017;35:6-19. |
|